-transparent.png){kind=logo}
Seventeen analogues of the tumor-promoting agent anthralin were tested for the same biological property by repeated skin application on mouse skin using female ICR/Ha Swiss mice, after a single application of a subcarcinogenic dose of 7,12-dimethylbenz[a]anthracene. Seven of the compounds tested are new compounds. They are 1,8-diacetoxy-9-anthrone, 1,8-dimyristoyloxy-9-anthrone, 1,8-dihydroxy-10-acetyl-9-anthrone, 1,8-dihydroxy-10-myristoyl-9-anthrone, 1,8,10-trihydroxy-9-anthrone, 1,8-dihydroxy-9,10-dihydroanthracene, and myristoyljuglone. All compounds were used in pure form for the bioassays. Of the 17 test compounds four showed notable tumor-promoting activity. They are 1,8-dihydroxy-10-acetyl-9-anthrone, 1,8-dihydroxy-10-myristoyl-9-anthrone, 1-hydroxy-9-anthrone, and juglone. In order to determine whether there is any relationship between tumor-promoting activity and metal chelation in this series, the chelating abilities of anthralin and of its inactive analogue 1,8-dihydroxyanthraquinone were examined using the bivalent metal ions Cu(II), Zn(II), Mn(II), Mg(II), and Ca(II). No relationship between chelation and tumor-promoting ability was found.
B L Van Duuren, and
A Segal, and
S S Tseng, and
G M Rusch, and
G Loewengart, and
U Maté, and
D Roth, and
A Smith, and
S Melchionne, and
I Seidman
June 1984,
Cancer letters,
B L Van Duuren, and
A Segal, and
S S Tseng, and
G M Rusch, and
G Loewengart, and
U Maté, and
D Roth, and
A Smith, and
S Melchionne, and
I Seidman
January 1983,
Carcinogenesis,
B L Van Duuren, and
A Segal, and
S S Tseng, and
G M Rusch, and
G Loewengart, and
U Maté, and
D Roth, and
A Smith, and
S Melchionne, and
I Seidman
October 1977,
Archiv der Pharmazie,
B L Van Duuren, and
A Segal, and
S S Tseng, and
G M Rusch, and
G Loewengart, and
U Maté, and
D Roth, and
A Smith, and
S Melchionne, and
I Seidman
January 1989,
The Journal of investigative dermatology,
B L Van Duuren, and
A Segal, and
S S Tseng, and
G M Rusch, and
G Loewengart, and
U Maté, and
D Roth, and
A Smith, and
S Melchionne, and
I Seidman
October 1977,
Archiv der Pharmazie,
B L Van Duuren, and
A Segal, and
S S Tseng, and
G M Rusch, and
G Loewengart, and
U Maté, and
D Roth, and
A Smith, and
S Melchionne, and
I Seidman
February 1969,
Hoppe-Seyler's Zeitschrift fur physiologische Chemie,
B L Van Duuren, and
A Segal, and
S S Tseng, and
G M Rusch, and
G Loewengart, and
U Maté, and
D Roth, and
A Smith, and
S Melchionne, and
I Seidman
January 1986,
Medical biology,
B L Van Duuren, and
A Segal, and
S S Tseng, and
G M Rusch, and
G Loewengart, and
U Maté, and
D Roth, and
A Smith, and
S Melchionne, and
I Seidman
July 1978,
Experientia,
B L Van Duuren, and
A Segal, and
S S Tseng, and
G M Rusch, and
G Loewengart, and
U Maté, and
D Roth, and
A Smith, and
S Melchionne, and
I Seidman
January 1975,
Pharmaceutica acta Helvetiae,
B L Van Duuren, and
A Segal, and
S S Tseng, and
G M Rusch, and
G Loewengart, and
U Maté, and
D Roth, and
A Smith, and
S Melchionne, and
I Seidman
February 1967,
Klinische Wochenschrift,
